Related Experiment Video
Updated: May 13, 2026
09:21
Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
Published on: July 7, 2023
Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery
Silvia Mandel1, Tamar Amit, Limor Kalfon
1Eve Topf Center for Neurodegenerative Diseases Research, Department of Pharmacology, Faculty of Medicine, Technion, Efron Street, PO Box 9697, Haifa 31096, Israel +972 4 8295289 ; +972 4 8513145 ; mandel@tx.technion.ac.il.
Expert Opinion on Drug Discovery
|March 19, 2013
Summary
Parkinson's disease (PD) involves vulnerable brain cells and protein buildup. Gene expression studies in PD brains reveal molecular signatures for early diagnosis and potential disease-modifying treatments.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Parkinson's disease (PD) pathogenesis involves dopaminergic neuron vulnerability to oxidative stress and impaired protein clearance.
- Microarray transcriptomic studies in human substantia nigra (SN) from PD brains confirm these mechanisms and elucidate underlying molecular pathways.
Purpose of the Study:
- To review recent gene expression profiling studies in sporadic PD postmortem SN.
- To identify gene candidates as potential molecular signatures for early PD diagnosis.
- To discuss the role of transcriptomics and proteomics in developing neuroprotective and disease-modifying drugs for PD.
Main Methods:
- Review of recent gene expression profiling studies (transcriptomics) in postmortem SN tissue from sporadic Parkinson's disease patients.
- Analysis of microarray data to identify differentially expressed genes.
- Discussion of proteomic approaches for drug discovery.
Main Results:
- Gene expression profiling studies have provided insights into molecular pathways in PD.
- Identified potential gene candidates that may serve as molecular signatures for early PD diagnosis.
- Highlighted the potential of transcriptomics and proteomics in identifying therapeutic targets.
Conclusions:
- Gene expression profiling is a valuable tool for understanding PD pathology.
- Identified gene candidates show promise for early PD diagnosis.
- Transcriptomics and proteomics are crucial for developing novel neuroprotective and disease-modifying therapies for Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...